Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosutinib in pediatric chronic myeloid leukemia
NL-OMON59328Phase 2Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of bosutinib in chronic myelogenous leukemia (CML) (2 arms), sponsored by Erasmus MC. Primary endpoints: Dose-limiting toxicities, Bosutinib pharmacokinetics in Phase 1 and 3 more. Started Sep 2016; status: active, not recruiting.
02
Drugs
bosutinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NL-OMON59328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59328.